title: A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in human leukocyte antigen (HLA)-identical live donor renal transplantation.
abstract: BACKGROUND
  Few prospective trials in human leukocyte antigen (HLA) identical living donor (LD) renal transplantation exist. This prospective study evaluated a corticosteroid (CS)-free, calcineurin inhibitor (CNI) minimization immunosuppressive regimen in HLA-identical LD renal transplant recipients.
  
  
  METHODS
  Twenty HLA-identical LD recipients were prospectively enrolled. Immunosuppression included mycophenolate mofetil (MMF) (2 g/day), tacrolimus (target trough 4-8 ng/mL), sirolimus (target trough 6-10 ng/mL), and no pre- or postoperative steroids. In the absence of prior rejection, tacrolimus was discontinued at posttransplant day 120 and sirolimus at 1 year, leaving patients on MMF monotherapy.
  
  
  RESULTS
  Tacrolimus was successfully withdrawn in 94% of patients (16/17). One hundred percent (15/15) of patients who reached 1-year posttransplant had sirolimus discontinued. Ninety-four percent (17/18) of patients remain off CSs. Mean serum creatinine at 6, 12, and 24 months were 1.38+/-0.32, 1.35+/-0.37, and 1.25+/-0.29 mg/dL; corresponding mean calculated creatinine clearance estimates were 70+/-18, 73+/-17, and 72+/-15 mL/min. Acute cellular rejection, chronic allograft nephropathy, and CNI toxicity were not observed. Death-censored graft survival was 100% at last follow-up.
  
  
  CONCLUSIONS
  A CS-free, CNI minimization immunosuppressive regimen with weaning to MMF monotherapy provides excellent renal function, graft survival, and patient survival in HLA-identical LD renal transplant recipients.
authors.affiliation: Department of Surgery, Division of Transplantation, University of Cincinnati, Cincinnati, OH 45267-0585, USA.
authors.forename: Jennifer K
authors.initials: JK
authors.lastname: Walker
authors.forename: Rita R
authors.initials: RR
authors.lastname: Alloway
authors.forename: Prabir
authors.initials: P
authors.lastname: Roy-Chaudhury
authors.forename: Gautham
authors.initials: G
authors.lastname: Mogilishetty
authors.forename: Michael A
authors.initials: MA
authors.lastname: Cardi
authors.forename: Nicole A
authors.initials: NA
authors.lastname: Weimert
authors.forename: Adele H
authors.initials: AH
authors.lastname: Rike
authors.forename: M Roy
authors.initials: MR
authors.lastname: First
authors.forename: E Steve
authors.initials: ES
authors.lastname: Woodle
mesh_terms: D000305:Adrenal Cortex Hormones; D001794:Blood Pressure; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000097:blood / Q000378:metabolism; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D019520:Living Donors; D011446:Prospective Studies; D012189:Retrospective Studies; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D000305:Adrenal Cortex Hormones; D006680:HLA Antigens; D007166:Immunosuppressive Agents; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D014280:Triglycerides; D002784:Cholesterol; D003404:Creatinine